November 29, 2018
Ken Romeril, CEO Myeloma New Zealand Charitable Trust invites you to the Myeloma New Zealand Christmas Function 12 December, 5.00pm at BNZ Partners Centre, Level 10 Ricoh House, 1 Victoria St Wellington RSVP by Friday 7 December to
Continue Reading
The U.S. Food and Drug Administration (FDA) has granted P-BCMA-101, Poseida Therapeutics’ CAR T-cell therapy and lead product candidate, the Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of relapsed or refractory multiple myeloma. Preliminary results from a Phase 1 trial (NCT03288493) suggest the candidate is safe and may have superior effectiveness compared with other CAR T-cell therapies. The RMAT designation...
Continue Reading
There has been activity with chimeric antigen receptor (CAR) T cells in patients with relapsed diffuse large B-cell lymphoma (DLBCL), but Charalambos (Babis) Andreadis, MD, MSCE, says there are still several things to consider before choosing this treatment option for a patient. “It’s something that we’re very excited about, especially for patients with relapsed disease. We also...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand